Cervical cancer (CC) is the fourth most common cancer among women globally. The key to preventing and treating CC is early detection, diagnosis, and treatment. This study aimed to develop an interpretable model for predicting CC risk using routine bl...
Cervical cancer (CC) is a major cause of mortality in women, with stagnant survival rates, highlighting the need for improved prognostic models. This study aims to develop and compare machine learning models for predicting five-year cause-specific su...
Cervical cancer is a major cause of mortality among women, particularly in low-income countries with insufficient screening programs. Manual cytological examination is time-consuming, error-prone and subject to inter-observer variability. Automated a...
This study assessed the acceptability of CITOBOT, a device for early cervical cancer screening in a real-world pilot setting as part of a translational research project aimed at designing and clinically validating a portable, cost-effective device su...
Cervical cancer is one of the most aggressive malignant tumours of the reproductive system, posing a significant global threat to women's health. Accurately segmenting cervical tumours in MR images remains a challenging task due to the complex charac...
To facilitate implementation of plan-of-the-day (POTD) selection for treating locally advanced cervical cancer (LACC), we developed a POTD assessment tool for CBCT-guided radiotherapy (RT). A female pelvis segmentation model (U-Seg3) is combined with...
The screening and monitoring of microRNAs as cancer molecular biomarkers is clinically significant, but traditional methods lack sufficient sensitivity, accuracy, and convenience. The CRISPR-colorimetric lateral flow assay (CLFA) integration offers a...
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Jun 11, 2025
Cervical cancer remains a leading cause of cancer-related death among women globally, despite the availability of effective prevention through human papillomavirus (HPV) vaccination and HPV-based screening. This review explores the state-of-the-art t...
High-dose-rate (HDR) brachytherapy is integral to the standard-of-care for locally advanced cervical cancer (LACC). Currently, selection of brachytherapy applicators relies on physician's clinical experience, which can lead to variability in treatmen...
Molecular medicine (Cambridge, Mass.)
May 30, 2025
BACKGROUND: Cervical cancer screening programs are increasingly relying on sensitive molecular approaches as primary tests to detect high-risk human papillomaviruses (hrHPV), the causative agents of cervix cancer. Although hrHPV infection is a pre-re...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.